![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Oxonica | LSE:OXN | London | Ordinary Share | GB00B0D09P49 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.125 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMOXN RNS Number : 2161V Oxonica plc 07 July 2009 7 July 2009 Oxonica plc ("Oxonica" or the "Company") Further to the announcement on 18 June 2009 of Oxonica's intention to seek shareholders' approval for the cancellation of the Company's admission to trading on AIM, Oxonica is pleased to announce that it will be posting a circular to shareholders today. The circular will be available on the Company's website at www.oxonica.com Oxonica today confirms that an application has been made for the cancellation of admission of the ordinary shares of the Company from trading on the AIM market of the London Stock Exchange. The general meeting of the Company will take place on 24 July 2009 at Hammonds LLP, 7 Devonshire Square, London, EC2M 4YH at 11.00 a.m. If the Cancellation Resolution is passed by the requisite majority, the Cancellation is expected to become effective as at 7.00 a.m. on 4 August 2009. Reasons for seeking the Cancellation Having carefully reviewed the position and consulted with the Company's advisers and a number of its major Shareholders, the Board of Directors of the Company (the "Board") has concluded that it is no longer in the Company's best interests to maintain the admission of the Shares to trading on AIM. The Board is concerned by a number of factors, including the relatively small total market capitalisation of the Company, the small free float, the limited trading volumes in the Shares and the significant direct and indirect costs of compliance with the AIM Rules for Companies (the "AIM Rules"), which the Board estimates to be at least GBP150,000 per annum. The resolution to cancel the admission to trading on AIM requires the approval of not less than 75 per cent. of those present and entitled to vote or voting by proxy at the General Meeting. This majority is required by rule 41 of the AIM Rules. It is the intention of the Board for the Company to remain as a public limited company and not to re-register as a private company. This is in order for the Company to retain the ability to make new offers of shares to the public. How Shareholders will be able to effect Share Transactions Whilst the Board believes that the proposed Cancellation is in the Shareholders' interests, it has evaluated alternative arrangements to enable Shareholders to continue to trade their Shares after the Cancellation. In the event that the Cancellation is approved, the Board intends to apply for the Shares to be traded on Sharemark. Sharemark is a periodic auction-based dealing facility offering smaller companies a simple, flexible and cost effective service through which their shares can be traded. The facility is operated by The Share Centre Limited, which is a member firm of the Exchange and is authorised and regulated by the Financial Services Authority. Sharemark is not a recognised investment exchange, recognised clearing house or regulated market within the meaning of the Markets in Financial Instruments Directive. The Sharemark dealing facility constitutes a Multilateral Trading Facility. Transactions are matched at a single auction price. The frequency of auction deals is determined on admission to Sharemark and is based primarily on the projected liquidity of the market in the company's securities. All orders for dealing within Sharemark are subject to continuous price display on Sharemark's website (www.sharemark.com) on an anonymous basis. This is to ensure transparency of price and volume. Where appropriate, the indicative auction price is also displayed. On the basis that the Company's application to Sharemark is successful, which the Company expects it to be, further details of Sharemark including how Shareholders will be able to effect share transactions will be provided to the Shareholders. If Shareholders wish to sell their Shares on AIM, they must do so prior to the Cancellation becoming effective (such Cancellation will occur no earlier than five clear business days after the General Meeting and it is expected that trading in the Shares on AIM will cease at the close of business on 3 August 2009, with Cancellation being effective at 7.00 a.m. on 4 August 2009). EFFECT OF THE PROPOSAL ON SHAREHOLDERS After the Cancellation, the price which investors may realise for their Shares, when they are able to do so, may be influenced by a large number of factors, some of which are specific to the Company and others of which are extraneous. Shareholders who hold Shares in the Company through a PEP or ISA will be required to dispose of their Shares if the Cancellation becomes effective as the Shares will no longer be "qualifying shares" for the purpose of a PEP or an ISA. Shareholders who remain a shareholder in the Company after the Cancellation should be aware that the value of the Shares could go down as well as up, and investors may not recover their original investment. It is possible that the Company may require additional funds to respond to business challenges and to further develop its business. If, after the Cancellation, the Company raises additional funds through further issues of equity, existing shareholders could suffer a dilution. However, your attention is drawn to the Board's proposals in relation to corporate governance and shareholder protections below. Shareholders should note that, following conclusion of the Cancellation, the Company will remain subject to the provisions of the City Code on Takeovers and Mergers. However, the regulatory regime imposed through the AIM Rules, which applies solely to companies with shares trading on AIM, will no longer apply. corporate governance AND SHAREHOLDER PROTECTIONs Companies traded on Sharemark are required to comply with the Sharemark Code of Practice (the "Code of Practice"), which includes the requirement for companies to publish annual accounts no later than six months after the end of the financial period to which they relate and a half yearly report in respect of the first six month period of any financial period no later than three months after the end of the period to which they relate. Companies are required to have proper regard to corporate governance and maintain corporate governance procedures commensurate with the size of its business. Companies are also required to adopt a code on directors' dealings in line with the UK Listing Authority's Model Code on Directors' Dealings and comply with the UK Market Abuse and Insider Dealing regimes. The Board has carefully reviewed the Code of Practice and consider it appropriate and in the interests of good corporate governance to extend the requirements under the Code of Practice. Accordingly, the Company will give an undertaking to Sharemark on its application becoming successful that it will comply with a number of additional requirements, including: notifying the Shareholders of any substantial transactions which exceed 20 per cent. in any tests adopted by the Board based on gross assets, profits, turnover, consideration to market capitalisation and gross capital (the "Class Tests"), notifying Shareholders of any "related party" transactions which exceed 10 per cent. in any of the Class Tests, notifying and obtaining the necessary consent of Shareholders to a "reverse takeover", maintaining a comprehensive and detailed website, disclosing to Shareholders any changes in the Board or major Shareholders, having at least two non-executive directors of which one shall be an independent non-executive director and maintaining its audit and remuneration committees comprising at least two non-executive directors. The Company will also continue to seek the following resolutions at each annual general meeting ("AGM") (as it has done at previous AGMs): (a) the authority under section 80 of the Companies Act 1985 (the "Act") to allot shares up to the aggregate nominal amount of the authorised but unissued share capital of the Company at the date of the AGM; and (b) the disapplication of pre-emption rights on the issue of new shares in the Company pursuant to section 95 of the Act provided that this authority is limited to: (i) the allotment of shares in connection with a rights issue; and (ii) the allotment (otherwise than pursuant to (i) above) of shares up to an aggregate nominal amount representing no more than 10 per cent. of the issued share capital of the Company at the date of the AGM. Such authorities shall expire at the next AGM or, if earlier, 15 months following the passing of the resolutions. GROUP STRATEGY As set out in the Group's 2008 Annual Report and the AGM Statement issued on 18 June 2009, the Board's objective is to improve the profitability of Oxonica and ensure that the Group has a sustainable position from which to build for the future. It is the Board's intention to achieve this within the Group's current resources. Oxonica's strategy was set-out in the AIM Admission Document issued in July 2005. This document stated that the Group's strategy was to introduce products to large end user markets, to establish the customer value proposition, create customer demand and outsource manufacturing. The objective was then to seek to form partnerships with international brand owners to maximise market reach. Having developed product offerings in all of its businesses, Oxonica is now focusing on partnering the Group's businesses to secure profitable platforms for growth. In 2008, Oxonica's Diagnostics business was partnered with BD and this enabled the Group to significantly reduce costs and cash burn in its US operations. The Company is currently in discussions with potential partners for its three remaining businesses. The structure of the resulting relationships will be announced on completion of the negotiations. It is anticipated that on completion of this strategy the Group's income will consist primarily of royalty income generated by partners' product sales. This strategy will facilitate further reductions in the Group's cost base resulting in a business that should generate positive earnings and cash flow in the medium term as the Group's strategic partners leverage their infrastructures to increase sales. It is envisaged that the earnings generated from the Group's various royalty incomes going forward will be returned to shareholders through dividends or share buy-backs as appropriate, or alternatively, invested in new opportunities. CHANGES TO THE BOARD As announced on 24 June 2009, Dr Kevin Matthews, Oxonica's CEO, has informed the Company of his intention to resign from the Board and will leave the Company on 29 September 2009. In addition, Ed Weeks currently the senior independent director and Chairman of the Remuneration Committee will step down from the Board on the same date. Gordon Ringold will remain on the Board until such time as the Security business is successfully partnered. The Company is commencing the search for an executive director to lead the future development of Oxonica and ultimately it is envisaged that the Board will consist of an executive director, Richard Farleigh as non-executive chairman and George Elliott as the independent non-executive director. EXPECTED TIMETABLE OF PRINCIPAL EVENTS In accordance with rule 41 of the AIM Rules, the Company has notified the Exchange of its intention to cancel admission of its AIM securities. Set out below is the expected timetable of principal events: +----------------------------------------------------+-------------------------+ | Announcement of General Meeting | 7 July 2009 | +----------------------------------------------------+-------------------------+ | Latest time and date for receipt of completed | 11.00 a.m. on 22 July | | forms of proxy to be valid at the General Meeting | 2009 | +----------------------------------------------------+-------------------------+ | General Meeting | 11.00 a.m. on 24 July | | | 2009 | +----------------------------------------------------+-------------------------+ | Last day of dealing in Shares | Close of trading on 3 | | | August 2009 | +----------------------------------------------------+-------------------------+ | Cancellation of admission to trading on AIM | 7.00 a.m. on 4 August | | effective from | 2009 | +----------------------------------------------------+-------------------------+ Each of the times and dates in the above timetable is subject to change. If any details in the above timetable should change, the revised times and dates will be notified to Shareholders by means of an announcement through a Regulatory Information Service. Recommendation The Board considers the Cancellation to be fair and reasonable and in the best interests of the Company and the Shareholders as a whole. Accordingly, the Board recommends that you vote in favour of the Resolution to be proposed at the General Meeting. The Board intends to vote in favour of the Resolution in respect of their own shareholding interests, representing 13,783,542 Shares (approximately 21.0 per cent. of the issued share capital of the Company) in aggregate. In addition, the Company has received irrevocable undertakings from various of its Shareholders (including from the Board in respect of their shareholdings) to vote in favour of the Resolution, representing 32,596,583 Shares (approximately 49.7 per cent. of the issued share capital of the Company) in aggregate. For further information, please contact: Oxonica plc 01865 856 728 Kevin Matthews, Chief Executive Officer Richard Clarke, Chief Financial Officer Panmure Gordon 020 7459 3600 Hugh Morgan Andrew Potts Notes to Editors About Oxonica plc - www.oxonica.com Oxonica (AIM: OXN.L) is a leading nanomaterials group with products already launched into international markets. Oxonica's leading product is Envirox(TM) Fuel Borne Catalyst - a nanocatalyst improving fuel economy and reducing emissions. The Group has also developed Optisol(TM), a photostable UV protection system designed to optimise the performance of quality sunscreens and anti-premature ageing products, and generates licence and development revenue from activities in the clinical diagnostics and security markets. This information is provided by RNS The company news service from the London Stock Exchange END MSCILFLRDTIRIIA
1 Year Oxonica Chart |
1 Month Oxonica Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions